Y Intercept Hong Kong Ltd Invests $2.28 Million in Haemonetics Corporation $HAE

Y Intercept Hong Kong Ltd acquired a new stake in Haemonetics Corporation (NYSE:HAE) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 46,863 shares of the medical instruments supplier’s stock, valued at approximately $2,284,000. Y Intercept Hong Kong Ltd owned 0.10% of Haemonetics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its position in Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Haemonetics by 59.4% in the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 165 shares during the period. Versant Capital Management Inc boosted its stake in shares of Haemonetics by 216.4% in the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 567 shares in the last quarter. Byrne Asset Management LLC acquired a new position in Haemonetics during the third quarter worth $42,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in Haemonetics in the second quarter worth $64,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on HAE. JPMorgan Chase & Co. upped their price target on shares of Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research note on Friday, December 12th. Barrington Research upped their target price on shares of Haemonetics from $90.00 to $93.00 and gave the stock an “outperform” rating in a research report on Monday, January 12th. Citigroup reduced their price target on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. Mizuho upped their price target on Haemonetics from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Finally, CJS Securities raised Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.40.

Haemonetics Trading Down 2.6%

Haemonetics stock opened at $66.10 on Thursday. The stock has a 50-day moving average price of $78.90 and a 200 day moving average price of $65.57. Haemonetics Corporation has a 52 week low of $47.31 and a 52 week high of $87.32. The stock has a market cap of $3.09 billion, a PE ratio of 19.33, a P/E/G ratio of 1.41 and a beta of 0.29. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.15. The business had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company’s quarterly revenue was down 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Equities research analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.